Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$62,424,863,000 | -$75,367 | -$58,983 | -$66,052 |
| Dep. & Amort. | $117,052,000 | $114 | $44 | $205 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $8,897,887,000 | $5,385 | $5,547 | $7,711 |
| Change in WC | $0 | -$3,018 | $4,753 | -$1,684 |
| Other Non-Cash | $1,580,487,000 | $4,092 | $5,665 | $3,147 |
| Operating Cash Flow | -$51,829,437,000 | -$68,794 | -$42,973 | -$56,675 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | $0 | $0 | $0 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $0 | $0 | $0 | $0 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | -$4 | $19,768 | -$2,319 |
| Stock Issued | $25,396,398,000 | $60,334 | $30,024 | $62,307 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $44,984,984,000 | $0 | -$824 | -$394 |
| Financing Cash Flow | $44,984,984,000 | $60,329 | $48,969 | $59,594 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$6,844,453,000 | -$8,464 | $5,995 | $2,919 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $14,927,538,000 | $23,392 | $17,397 | $14,477 |
| End Cash | $8,083,085,000 | $14,928 | $23,392 | $17,397 |
| Free Cash Flow | -$51,829,437,000 | -$68,794 | -$42,973 | -$56,675 |